Extended Data Fig 6: Association of PNET subtypes with ALT status.
From: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors
a,c, Tumor size in all PNET subtypes in the Dutch (a) (n = 56 independent tumors) and the MGH (c) (n = 61 independent tumors) cohorts. Bars represent mean ± s.d. P values for differences in size of primary ARX+ and PDX1+ tumors determined by the two-sided Mann–Whitney U-test. b,d, Analyses of recurrence-free survival in the Dutch (b) (n = 30 cases) and MGH (d) (n = 35 cases) cohorts when ARX+ and PDX1+ tumors were considered separately, ungrouped from DP and DN tumors. P values and HRs were determined using two-sided log-rank and Mantel–Haenszel tests, respectively. e,f, Representative (e) (1 example each from 25 independent ALT+ and 87 independent ALT− cases) and aggregate (f) (n = 112 biologically independent cases) results of telomere-specific FISH in cases classified as positive or negative for ALT. The statistical test was two-sided. g, Kaplan–Meier analysis of disease-free survival in all 112 cases with ALT data from both cohorts, without consideration of PNET subtype.
